-
Something wrong with this record ?
Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications
L. Tesarova, K. Jaresova, P. Simara, I. Koutna
Language English Country Switzerland
Document type Journal Article
Grant support
CZ.02.1.01/0.0/0.0/16_013/0001826
European Regional Development Fund - project CZECRIN_4 PACIENTY
LQ1605
MEYS CR, NPU II
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
32731615
DOI
10.3390/ijms21155366
Knihovny.cz E-resources
- MeSH
- Cell Differentiation drug effects immunology MeSH
- Fibroblast Growth Factor 2 immunology pharmacology MeSH
- Immunosuppression Therapy * MeSH
- Humans MeSH
- Mesenchymal Stem Cells cytology immunology MeSH
- Cell Proliferation drug effects MeSH
- Umbilical Cord cytology immunology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Mesenchymal stem cells (MSCs) have become a promising tool in cellular therapy for restoring immune system haemostasis; however, the success of clinical trials has been impaired by the lack of standardized manufacturing processes. This study aims to determine the suitability of source tissues and culture media for the production of MSC-based advanced therapy medicinal products (ATMPs) and to define parameters to extend the set of release criteria. MSCs were isolated from umbilical cord (UC), bone marrow and lipoaspirate and expanded in three different culture media. MSC phenotype, proliferation capacity and immunosuppressive parameters were evaluated in normal MSCs compared to primed MSCs treated with cytokines mimicking an inflammatory environment. Compared to bone marrow and lipoaspirate, UC-derived MSCs (UC-MSCs) showed the highest proliferative capacity, which was further enhanced by media supplemented with bFGF, while the cells maintained their immunosuppressive characteristics. Moreover, UC-MSCs expanded in the bFGF-enriched medium were the least sensitive to undesirable priming-induced changes in the MSC phenotype. Surface markers and secreted factors were identified to reflect the cell response to inflammatory priming and to be variable among MSCs from different source tissues. This study demonstrates that UC is a favorable cell source for manufacturing MSC-based ATMPs for immunosuppressive applications. UC-MSCs are able to use the bFGF-enriched medium for higher cell yields without the impairment of immunosuppressive parameters and undesirable phenotype changes after inflammatory preconditioning of MSCs before transplantation. Additionally, immunosuppressive parameters were identified to help finding predictors of clinically efficient MSCs in the following clinical trials.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012338
- 003
- CZ-PrNML
- 005
- 20210714100043.0
- 007
- ta
- 008
- 210420s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms21155366 $2 doi
- 035 __
- $a (PubMed)32731615
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Tesarova, Lenka $u International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic ; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
- 245 10
- $a Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications / $c L. Tesarova, K. Jaresova, P. Simara, I. Koutna
- 520 9_
- $a Mesenchymal stem cells (MSCs) have become a promising tool in cellular therapy for restoring immune system haemostasis; however, the success of clinical trials has been impaired by the lack of standardized manufacturing processes. This study aims to determine the suitability of source tissues and culture media for the production of MSC-based advanced therapy medicinal products (ATMPs) and to define parameters to extend the set of release criteria. MSCs were isolated from umbilical cord (UC), bone marrow and lipoaspirate and expanded in three different culture media. MSC phenotype, proliferation capacity and immunosuppressive parameters were evaluated in normal MSCs compared to primed MSCs treated with cytokines mimicking an inflammatory environment. Compared to bone marrow and lipoaspirate, UC-derived MSCs (UC-MSCs) showed the highest proliferative capacity, which was further enhanced by media supplemented with bFGF, while the cells maintained their immunosuppressive characteristics. Moreover, UC-MSCs expanded in the bFGF-enriched medium were the least sensitive to undesirable priming-induced changes in the MSC phenotype. Surface markers and secreted factors were identified to reflect the cell response to inflammatory priming and to be variable among MSCs from different source tissues. This study demonstrates that UC is a favorable cell source for manufacturing MSC-based ATMPs for immunosuppressive applications. UC-MSCs are able to use the bFGF-enriched medium for higher cell yields without the impairment of immunosuppressive parameters and undesirable phenotype changes after inflammatory preconditioning of MSCs before transplantation. Additionally, immunosuppressive parameters were identified to help finding predictors of clinically efficient MSCs in the following clinical trials.
- 650 _2
- $a buněčná diferenciace $x účinky léků $x imunologie $7 D002454
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a fibroblastový růstový faktor 2 $x imunologie $x farmakologie $7 D016222
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a imunosupresivní léčba $7 D007165
- 650 _2
- $a mezenchymální kmenové buňky $x cytologie $x imunologie $7 D059630
- 650 _2
- $a pupečník $x cytologie $x imunologie $7 D014470
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jaresova, Klara $u International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic ; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
- 700 1_
- $a Simara, Pavel $u International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic ; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
- 700 1_
- $a Koutna, Irena $u International Clinical Research Center, St. Anne's University Hospital, Pekarska 53, 65691 Brno, Czech Republic ; Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 21, č. 15 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32731615 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210714100041 $b ABA008
- 999 __
- $a ok $b bmc $g 1650666 $s 1132717
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 21 $c 15 $e 20200728 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_013/0001826 $p European Regional Development Fund - project CZECRIN_4 PACIENTY
- GRA __
- $a LQ1605 $p MEYS CR, NPU II
- LZP __
- $a Pubmed-20210420
